Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

Completed · Phase 1

Conditions studied: Alzheimers Disease

In brief

The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.

Key facts

Study ID
NCT00439010
Run by
Molecular NeuroImaging
People needed
30
Starts
2007-02-01
Expected to finish
2008-01-01
Last updated by the study team
2008-04-24

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.